MA29400B1 - Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence - Google Patents

Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence

Info

Publication number
MA29400B1
MA29400B1 MA30310A MA30310A MA29400B1 MA 29400 B1 MA29400 B1 MA 29400B1 MA 30310 A MA30310 A MA 30310A MA 30310 A MA30310 A MA 30310A MA 29400 B1 MA29400 B1 MA 29400B1
Authority
MA
Morocco
Prior art keywords
dementia
disorder
prevention
agent
treatment
Prior art date
Application number
MA30310A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29400B1 publication Critical patent/MA29400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN AGENT POUR LA PRÉVENTION OU LE TRAITEMENT D'UN TROUBLE NOCTURNE DU COMPORTEMENT ASSOCIÉ À LA DÉMENCE, COMPRENANT DU (S)-N-[2-(1,6,7,8-TÉTRAHYDRO-2H-INDÉNO[5,4-B]FURANE-8- YL)ÉTHYLE]PROPIONAMIDE.
MA30310A 2005-04-04 2007-10-25 Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence MA29400B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107673 2005-04-04

Publications (1)

Publication Number Publication Date
MA29400B1 true MA29400B1 (fr) 2008-04-01

Family

ID=37073568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30310A MA29400B1 (fr) 2005-04-04 2007-10-25 Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence

Country Status (20)

Country Link
US (1) US20090306200A1 (fr)
EP (1) EP1867642A4 (fr)
JP (1) JP5244384B2 (fr)
KR (1) KR20070118101A (fr)
CN (1) CN101146787A (fr)
AR (1) AR054246A1 (fr)
AU (1) AU2006231759A1 (fr)
BR (1) BRPI0609964A2 (fr)
CA (1) CA2601988A1 (fr)
CL (1) CL2009001914A1 (fr)
CR (1) CR9376A (fr)
IL (1) IL185936A0 (fr)
MA (1) MA29400B1 (fr)
MY (1) MY148806A (fr)
NO (1) NO20075600L (fr)
PE (1) PE20061292A1 (fr)
RU (1) RU2007140876A (fr)
TW (1) TW200637541A (fr)
WO (1) WO2006107027A1 (fr)
ZA (1) ZA200708444B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
CA3010727C (fr) 2016-01-08 2023-10-31 Takeda Pharmaceutical Company Limited Agent de traitement prophylactique ou therapeutique du delire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034239A (en) * 1961-04-05 1962-05-15 Arthur P Waterson Land leveler
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
AU2003258147A1 (en) * 2002-08-08 2004-02-25 Irm Llc Methods for treating circadian rhythm phase disturbances

Also Published As

Publication number Publication date
AR054246A1 (es) 2007-06-13
CR9376A (es) 2007-12-07
CA2601988A1 (fr) 2006-10-12
RU2007140876A (ru) 2009-05-20
WO2006107027A1 (fr) 2006-10-12
JP5244384B2 (ja) 2013-07-24
CN101146787A (zh) 2008-03-19
EP1867642A1 (fr) 2007-12-19
KR20070118101A (ko) 2007-12-13
TW200637541A (en) 2006-11-01
ZA200708444B (en) 2009-03-25
JPWO2006107027A1 (ja) 2008-09-25
BRPI0609964A2 (pt) 2011-10-11
EP1867642A4 (fr) 2009-04-01
US20090306200A1 (en) 2009-12-10
AU2006231759A1 (en) 2006-10-12
CL2009001914A1 (es) 2010-02-12
IL185936A0 (en) 2008-01-06
NO20075600L (no) 2007-12-21
MY148806A (en) 2013-05-31
PE20061292A1 (es) 2006-12-23

Similar Documents

Publication Publication Date Title
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
NL1026892A1 (nl) ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
EP1875894A3 (fr) Utilisation d'au moins un dérivé C-glycoside à titre d'agent apaisant
ATE368031T1 (de) Neue gamma secretase inhibitoren
TW200722100A (en) A therapeutic agent for a β related disorders
EP1858440A4 (fr) Alliages metalliques ameliores pour dispositifs medicaux
JO2578B1 (en) Compounds Theophene benzimidazole
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
MX2008001549A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.
NO20075599L (no) Profylaktisk eller terapeutisk middel mot depresjon eller angstforstyrrelser
WO2005044200A3 (fr) Procedes et compositions pour traiter des pathologies associees a la mcp-1
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
EP1773970A4 (fr) Formules de lubrifiants pour le traitement de toles
WO2005042021A3 (fr) Composition pharmaceutique contenant un agoniste des recepteurs beta-3-adrenergiques et un antagoniste alpha et/ou un inhibiteur de la 5-alpha-reductase
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
FR2890304B1 (fr) Un dispositif pour mesurer la resistance a la deformation d'une cornee.
DE60318661D1 (de) Schmieren des Notlaufrings
EP1867642A4 (fr) Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence
MA31993B1 (fr) Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate
FR2851947B1 (fr) Procede d'usinage d'une lentille ophtalmique.
MA53607B1 (fr) (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés